A Phase 1 Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, Peripheral T-Cell Lymphoma, or Cutaneous T-Cell Lymphoma

A phase 1 study was conducted to determine the dose-limiting toxicities and maximum tolerated dose (MTD) for bortezomib followed by romidepsin on days 1, 8, and 15 in patients with relapsed/refractory CLL/SLL or B- or T-cell lymphoma. Eighteen treated patients were evaluable for response. The MTD wa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Leuk Lymphoma
Hauptverfasser: Holkova, Beata, Yazbeck, Victor, Kmieciak, Maciej, Bose, Prithviraj, Ma, Shuo, Kimball, Amy, Tombes, Mary Beth, Shrader, Ellen, Wan, Wen, Weir-Wiggins, Caryn, Singh, Amanda, Hogan, Kevin T., Conine, Sarah, Sankala, Heidi, Roberts, John D., Shea, Thomas C., Grant, Steven
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2017
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5817887/
https://ncbi.nlm.nih.gov/pubmed/28103725
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2016.1276287
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge